Axonyx Initiates IND Studies of Tolserine Tartrate for Memory Improvement.Health & Medical Editors NEW YORK--(BW HealthWire)--Nov. 30, 2000 Axonyx Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : AXYX) announced today that the Company has initiated preclinical studies preclinical studies, n.pl a term used to describe research done before a clinical study. May be laboratory or epidemiologic research. necessary to file an Investigational New Drug Application (IND) with the Food & Drug Administration for Tolserine tartrate tartrate /tar·trate/ (tahr´trat) a salt of tartaric acid. tar·trate n. A salt or ester of tartaric acid. tartrate a salt of tartaric acid. , its fourth generation acetylcholinesterase inhibitor acetylcholinesterase inhibitor n. See cholinesterase inhibitor. . Tolserine was discovered at the National Institute of Aging/National Institutes of Health and licensed to Axonyx, which holds world-wide development rights. Tolserine demonstrated promising results in preclinical memory studies, in which rats were better able to maneuver through a complex maze than their control counterparts. Memory improved over fifty percent at previously tested dose levels. The Company expects Tolserine's therapeutic profile, with respect to brain penetration and memory enzyme targeting, to be quite favorable. "Tolserine's positive preclinical results give us the confidence to proceed, with the next goal of conducting human clinical trials. Tolserine has a high specificity for the enzyme acetylcholinesterase acetylcholinesterase /ac·e·tyl·cho·lin·es·ter·ase/ (AChE) (-ko?li-nes´ter-as) an enzyme present in the central nervous system, particularly in nervous tissue, muscle, and red cells, that catalyzes the hydrolysis of acetylcholine to , and this activity may allow use of this drug in the treatment of memory loss associated with degenerative diseases of the brain," stated Marvin S. Hausman, M.D., President & CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Axonyx. Phenserine, the Company's lead acetylcholinesterase inhibitor, is about to undergo a Phase II proof-of-concept study for Alzheimer's Disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. . Axonyx Inc. is a biotechnology company engaged in the discovery, acquisition and development of proprietary pharmaceutical compounds and new technologies useful in the diagnosis and treatment of Alzheimer's Disease and other memory disorders. This press release may contain forward-looking statements or predictions regarding the development of scientific assets. These statements represent our judgment and plan as of this date and are subject to uncertainties and risks that could materially affect the Company. Axonyx undertakes no obligation to publicly release the result of any revisions to such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion